血性悪性疾患患者の静脈内アセトアミノフェンによる重度の低血圧のリスク要因
Yu-Ri Choi1, Ji-In Park1, Seong-Sim An1
1Department of Pharmacy, Seoul St. Mary's Hospital, Seoul, Korea.
Pharmacoepidemiology and drug safety
|August 25, 2025
まとめ
静脈内アセトアミノフェンは,重度の低血圧を引き起こす可能性があります. 危険因子には高熱,急性腎臓損傷,細菌血症などがあり,血圧を注意深く監視することが必要です.
科学分野:
- 薬理学について
- クリティカル ケア 医療
- 血液学
背景:
- 静脈内アセトアミノフェン (AAP) は,その迅速な作用のために,重症患者の熱に対して頻繁に使用されます.
- しかし,静脈内AAPの後の低血圧のリスクは,特に脆弱な集団では,さらなる調査を必要とします.
研究 の 目的:
- 血行性悪性腫瘍患者の静脈内アセトアミノフェン投与後の重度の低血圧の危険因子を特定する.
主な方法:
- 静脈注射AAPを投与された入院血液腫瘍患者の遡及的研究.
- 重度の低血圧を経験した患者と,そうでない患者の比較
- リスク要因を特定するための単変数と多変数分析
主要な成果:
- 37人の患者が重度の低血圧を発症し,111人が対照群となった.
- 危険因子:投与前の体温上昇,急性腎臓損傷,細菌血症
- 投与前の平均動脈圧の上昇は,低血圧のリスクの低下と関連していました.
結論:
- 血性悪性腫瘍の患者で静脈内投与AAPを投与すると,重度の低血圧のリスクが発生します.
- 発熱,AKI,バクテレミアなどの既にある状態は,このリスクを高めます.
- AAPを静脈内投与する際の血圧の厳密なモニタリングは,患者の安全性にとって極めて重要です.
さらに関連する動画
関連する概念動画
Hemodialysis II: Procedure and Complications
129
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
129
Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Alterations in Blood Pressure
1.5K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
1.5K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114
Renal Failure: Dose Adjustments
153
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
153


